{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T19:58:01Z","timestamp":1770494281973,"version":"3.49.0"},"reference-count":80,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","theclinics.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Magnetic Resonance Imaging Clinics of North America"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.mric.2023.12.001","type":"journal-article","created":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T21:18:02Z","timestamp":1707513482000},"page":"233-251","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Neuromyelitis Optica Spectrum Disorders and Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease"],"prefix":"10.1016","volume":"32","author":[{"given":"John H.","family":"Rees","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Torge","family":"Rempe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ibrahim Sacit","family":"Tuna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mayra Montalvo","family":"Perero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shyamsunder","family":"Sabat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tara","family":"Massini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr.","given":"Joseph M.","family":"Yetto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.mric.2023.12.001_bib1","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1111\/bpa.12084","article-title":"Aquaporin-4 antibodies (NMO-IgG) as a serological marker of neuromyelitis optica: a critical review of the literature","volume":"23","author":"Jarius","year":"2013","journal-title":"Brain Pathol"},{"issue":"2","key":"10.1016\/j.mric.2023.12.001_bib2","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/cei.12271","article-title":"Neuromyelitis optica: clinical features, immunopathogenesis and treatment","volume":"176","author":"Jarius","year":"2014","journal-title":"Clin Exp Immunol"},{"issue":"4","key":"10.1016\/j.mric.2023.12.001_bib3","first-page":"1131","article-title":"Neuromyelitis optica spectrum disorders","volume":"28","author":"Costello","year":"2022","journal-title":"Continuum"},{"key":"10.1016\/j.mric.2023.12.001_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103286","article-title":"Impact of COVID-19 public health measures on myelin oligodendrocyte glycoprotein IgG-associated disorders in children","volume":"56","author":"Kaseka","year":"2021","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.mric.2023.12.001_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.102773","article-title":"The influence of smoking on the pattern of disability and relapse risk in AQP4-positive Neuromyelitis Optica Spectrum Disorder, MOG-Ab Disease and Multiple Sclerosis","volume":"49","author":"Messina","year":"2021","journal-title":"Mult Scler Relat Disord"},{"issue":"1","key":"10.1016\/j.mric.2023.12.001_bib6","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1159\/000087387","article-title":"Historical descriptions of multiple sclerosis","volume":"54","author":"Pearce","year":"2005","journal-title":"Eur Neurol"},{"issue":"1","key":"10.1016\/j.mric.2023.12.001_bib7","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1186\/s12974-019-1594-1","article-title":"The history of neuromyelitis optica. Part 2: \u201cSpinal amaurosis\u201d","volume":"16","author":"Jarius","year":"2019","journal-title":"or how it all began. J Neuroinflammation"},{"issue":"7","key":"10.1016\/j.mric.2023.12.001_bib8","first-page":"1354","article-title":"The case of the Marquis de Causan (1804): an early account of visual loss associated with spinal cord inflammation","volume":"259","author":"Jarius","year":"2012","journal-title":"J\u00a0Neurol"},{"key":"10.1016\/j.mric.2023.12.001_bib9","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1742-2094-10-8","article-title":"The history of neuromyelitis optica","volume":"10","author":"Jarius","year":"2013","journal-title":"J\u00a0Neuroinflammation"},{"issue":"4","key":"10.1016\/j.mric.2023.12.001_bib10","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1084\/jem.20050304","article-title":"IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel","volume":"202","author":"Lennon","year":"2005","journal-title":"J\u00a0Exp Med"},{"issue":"7","key":"10.1016\/j.mric.2023.12.001_bib11","doi-asserted-by":"crossref","first-page":"e1316","DOI":"10.1002\/cti2.1316","article-title":"Pathogenesis of autoimmune demyelination: from multiple sclerosis to neuromyelitis optica spectrum disorders and myelin oligodendrocyte glycoprotein antibody-associated disease","volume":"10","author":"Lopez","year":"2021","journal-title":"Clin Transl Immunology"},{"key":"10.1016\/j.mric.2023.12.001_bib12","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/1742-2094-8-184","article-title":"Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders","volume":"8","author":"Mader","year":"2011","journal-title":"J\u00a0Neuroinflammation"},{"issue":"5","key":"10.1016\/j.mric.2023.12.001_bib13","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1177\/135245850100700503","article-title":"Anti-MOG and anti-MBP antibody subclasses in multiple sclerosis","volume":"7","author":"Egg","year":"2001","journal-title":"Mult Scler"},{"issue":"5055","key":"10.1016\/j.mric.2023.12.001_bib14","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1126\/science.256.5055.385","article-title":"Appearance of water channels in Xenopus oocytes expressing red cell CHIP28 protein","volume":"256","author":"Preston","year":"1992","journal-title":"Science"},{"issue":"9","key":"10.1016\/j.mric.2023.12.001_bib15","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1038\/nrm1469","article-title":"From structure to disease: the evolving tale of aquaporin biology","volume":"5","author":"King","year":"2004","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"2","key":"10.1016\/j.mric.2023.12.001_bib16","doi-asserted-by":"crossref","first-page":"C426","DOI":"10.1152\/ajpcell.00298.2003","article-title":"Sevenfold-reduced osmotic water permeability in primary astrocyte cultures from AQP-4-deficient mice, measured by a fluorescence quenching method","volume":"286","author":"Solenov","year":"2004","journal-title":"Am J Physiol Cell Physiol"},{"issue":"1","key":"10.1016\/j.mric.2023.12.001_bib17","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1523\/JNEUROSCI.17-01-00171.1997","article-title":"Specialized membrane domains for water transport in glial cells: high-resolution immunogold cytochemistry of aquaporin-4 in rat brain","volume":"17","author":"Nielsen","year":"1997","journal-title":"J\u00a0Neurosci"},{"issue":"7","key":"10.1016\/j.mric.2023.12.001_bib18","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1523\/JNEUROSCI.18-07-02506.1998","article-title":"Aquaporin-4 water channel protein in the rat retina and optic nerve: polarized expression in M\u00fcller cells and fibrous astrocytes","volume":"18","author":"Nagelhus","year":"1998","journal-title":"J\u00a0Neurosci"},{"key":"10.1016\/j.mric.2023.12.001_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/B978-0-12-386043-9.00001-3","article-title":"Structure and functions of aquaporin-4-based orthogonal arrays of particles","volume":"287","author":"Wolburg","year":"2011","journal-title":"Int Rev Cell Mol Biol"},{"issue":"9451","key":"10.1016\/j.mric.2023.12.001_bib20","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/S0140-6736(04)17551-X","article-title":"A\u00a0serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis","volume":"364","author":"Lennon","year":"2004","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.mric.2023.12.001_bib21","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.it.2015.08.006","article-title":"Revisiting the mechanisms of CNS immune privilege","volume":"36","author":"Louveau","year":"2015","journal-title":"Trends Immunol"},{"issue":"1","key":"10.1016\/j.mric.2023.12.001_bib22","article-title":"Immune cell trafficking across the blood-brain barrier in the absence and presence of neuroinflammation","volume":"2","author":"Marchetti","year":"2020","journal-title":"Vasc Biol"},{"issue":"1","key":"10.1016\/j.mric.2023.12.001_bib23","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1148\/rg.2018170141","article-title":"Neuromyelitis optica spectrum disorders: spectrum of MR imaging findings and their differential diagnosis","volume":"38","author":"Dutra","year":"2018","journal-title":"Radiographics"},{"issue":"7","key":"10.1016\/j.mric.2023.12.001_bib24","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1177\/1352458515572406","article-title":"Demographic and clinical features of neuromyelitis optica: A review","volume":"21","author":"Pandit","year":"2015","journal-title":"Mult Scler"},{"key":"10.1016\/j.mric.2023.12.001_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102718","article-title":"Anti-MOG associated disorder-Clinical and radiological characteristics compared to AQP4-IgG+ NMOSD-A single-center experience","volume":"48","author":"Rempe","year":"2021","journal-title":"Mult Scler Relat Disord"},{"issue":"2","key":"10.1016\/j.mric.2023.12.001_bib26","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"issue":"17","key":"10.1016\/j.mric.2023.12.001_bib27","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.4103\/0366-6999.189046","article-title":"Clinical Features of Patients with Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders","volume":"129","author":"Chen","year":"2016","journal-title":"Chin Med J"},{"issue":"2","key":"10.1016\/j.mric.2023.12.001_bib28","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1212\/CPJ.0000000000000104","article-title":"Asymptomatic myelitis in neuromyelitis optica and autoimmune aquaporin-4 channelopathy","volume":"5","author":"Flanagan","year":"2015","journal-title":"Neurol Clin Pract"},{"issue":"8","key":"10.1016\/j.mric.2023.12.001_bib29","doi-asserted-by":"crossref","first-page":"e851","DOI":"10.1212\/WNL.0000000000200838","article-title":"Frequency of Asymptomatic Optic Nerve Enhancement in a Large Retrospective Cohort of Patients With Aquaporin-4+ NMOSD","volume":"99","author":"Shah","year":"2022","journal-title":"Neurology"},{"issue":"17","key":"10.1016\/j.mric.2023.12.001_bib30","doi-asserted-by":"crossref","first-page":"e1642","DOI":"10.1212\/WNL.0000000000006392","article-title":"Area postrema syndrome: Frequency, criteria, and severity in AQP4-IgG-positive NMOSD","volume":"91","author":"Shosha","year":"2018","journal-title":"Neurology"},{"issue":"14","key":"10.1016\/j.mric.2023.12.001_bib31","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1212\/WNL.0b013e318214332c","article-title":"Neuromyelitis optica unique area postrema lesions: nausea, vomiting, and pathogenic implications","volume":"76","author":"Popescu","year":"2011","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.mric.2023.12.001_bib32","doi-asserted-by":"crossref","first-page":"e110","DOI":"10.1212\/NXI.0000000000000110","article-title":"Aquaporin-4 autoimmunity","volume":"2","author":"Zekeridou","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"8\u20139","key":"10.1016\/j.mric.2023.12.001_bib33","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1177\/08830738221103085","article-title":"A\u00a0Comparison of Pediatric- and Adult-Onset Aquaporin-4 Immunoglobulin G-Positive Neuromyelitis Optica Spectrum Disorder: A Review of Clinical and Radiographic Characteristics","volume":"37","author":"Tarhan","year":"2022","journal-title":"J\u00a0Child Neurol"},{"issue":"8","key":"10.1016\/j.mric.2023.12.001_bib34","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1001\/jamaneurol.2014.775","article-title":"Autoimmune aquaporin-4 myopathy in neuromyelitis optica spectrum","volume":"71","author":"Guo","year":"2014","journal-title":"JAMA Neurol"},{"issue":"17","key":"10.1016\/j.mric.2023.12.001_bib35","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1212\/WNL.0b013e3182703ff7","article-title":"Two cases of lumbosacral myeloradiculitis with anti-aquaporin-4 antibody","volume":"79","author":"Takai","year":"2012","journal-title":"Neurology"},{"issue":"7\u20138","key":"10.1016\/j.mric.2023.12.001_bib36","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1080\/09273948.2021.1942499","article-title":"Neuromyelitis optica spectrum disorder and uveitis","volume":"30","author":"Carey","year":"2022","journal-title":"Ocul Immunol Inflamm"},{"issue":"1","key":"10.1016\/j.mric.2023.12.001_bib37","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/mus.21197","article-title":"Coexistence of myasthenia gravis and serological markers of neurological autoimmunity in neuromyelitis optica","volume":"39","author":"McKeon","year":"2009","journal-title":"Muscle Nerve"},{"issue":"4","key":"10.1016\/j.mric.2023.12.001_bib38","doi-asserted-by":"crossref","first-page":"e468","DOI":"10.1212\/NXI.0000000000000468","article-title":"Mortality in neuromyelitis optica is strongly associated with African ancestry","volume":"5","author":"Mealy","year":"2018","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"13","key":"10.1016\/j.mric.2023.12.001_bib39","doi-asserted-by":"crossref","first-page":"e1351","DOI":"10.1212\/WNL.0000000000012599","article-title":"CNS Demyelinating Attacks Requiring Ventilatory Support With Myelin Oligodendrocyte Glycoprotein or Aquaporin-4 Antibodies","volume":"97","author":"Zhao-Fleming","year":"2021","journal-title":"Neurology"},{"issue":"22","key":"10.1016\/j.mric.2023.12.001_bib40","doi-asserted-by":"crossref","first-page":"e2089","DOI":"10.1212\/WNL.0000000000006574","article-title":"Racial differences in neuromyelitis optica spectrum disorder","volume":"91","author":"Kim","year":"2018","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.mric.2023.12.001_bib41","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1002\/ana.24617","article-title":"Epidemiology of aquaporin-4 autoimmunity and neuromyelitis optica spectrum","volume":"79","author":"Flanagan","year":"2016","journal-title":"Ann Neurol"},{"issue":"4","key":"10.1016\/j.mric.2023.12.001_bib42","article-title":"Diagnostic value of aquaporin-4-IgG live cell based assay in neuromyelitis optica spectrum disorders","volume":"7","author":"Redenbaugh","year":"2021","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"10.1016\/j.mric.2023.12.001_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102522","article-title":"Risk of relapse in patients with neuromyelitis optica spectrum disorder: Recognition and preventive strategy","volume":"46","author":"Ma","year":"2020","journal-title":"Mult Scler Relat Disord"},{"issue":"9","key":"10.1016\/j.mric.2023.12.001_bib44","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1001\/archneurol.2012.314","article-title":"Epidemiology of neuromyelitis optica in the United States: a multicenter analysis","volume":"69","author":"Mealy","year":"2012","journal-title":"Arch Neurol"},{"issue":"5","key":"10.1016\/j.mric.2023.12.001_bib45","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1212\/WNL.53.5.1107","article-title":"The clinical course of neuromyelitis optica (Devic\u2019s syndrome)","volume":"53","author":"Wingerchuk","year":"1999","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.mric.2023.12.001_bib46","doi-asserted-by":"crossref","first-page":"e504","DOI":"10.1212\/NXI.0000000000000504","article-title":"Apheresis therapies for NMOSD attacks: A retrospective study of 207 therapeutic interventions","volume":"5","author":"Kleiter","year":"2018","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"4","key":"10.1016\/j.mric.2023.12.001_bib47","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1136\/jnnp-2017-316286","article-title":"Short delay to initiate plasma exchange is the strongest predictor of outcome in severe attacks of NMO spectrum disorders","volume":"89","author":"Bonnan","year":"2018","journal-title":"J\u00a0Neurol Neurosurg Psychiatr"},{"issue":"4","key":"10.1016\/j.mric.2023.12.001_bib48","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/cen3.12239","article-title":"Bevacizumab is safe in acute relapses of neuromyelitis optica","volume":"6","author":"Mealy","year":"2015","journal-title":"Clin Exp Neuroimmunol"},{"issue":"4","key":"10.1016\/j.mric.2023.12.001_bib49","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S1474-4422(20)30066-1","article-title":"Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"19","author":"Tahara","year":"2020","journal-title":"Lancet Neurol"},{"issue":"9","key":"10.1016\/j.mric.2023.12.001_bib50","first-page":"2003","article-title":"Comparison of the efficacy of azathioprine and rituximab in neuromyelitis optica spectrum disorder: a randomized clinical trial","volume":"264","author":"Nikoo","year":"2017","journal-title":"J\u00a0Neurol"},{"issue":"1","key":"10.1016\/j.mric.2023.12.001_bib51","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s12883-019-1261-2","article-title":"Effectiveness of rituximab in neuromyelitis optica: a meta-analysis","volume":"19","author":"Gao","year":"2019","journal-title":"BMC Neurol"},{"issue":"10","key":"10.1016\/j.mric.2023.12.001_bib52","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1002\/acn3.51451","article-title":"A\u00a0meta-analysis comparing first-line immunosuppressants in neuromyelitis optica","volume":"8","author":"Giovannelli","year":"2021","journal-title":"Ann Clin Transl Neurol"},{"issue":"10206","key":"10.1016\/j.mric.2023.12.001_bib53","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/S0140-6736(19)31817-3","article-title":"Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2\/3 trial","volume":"394","author":"Cree","year":"2019","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.mric.2023.12.001_bib54","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/S1474-4422(20)30078-8","article-title":"Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial","volume":"19","author":"Traboulsee","year":"2020","journal-title":"Lancet Neurol"},{"issue":"22","key":"10.1016\/j.mric.2023.12.001_bib55","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1056\/NEJMoa1901747","article-title":"Trial of satralizumab in neuromyelitis optica spectrum disorder","volume":"381","author":"Yamamura","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.mric.2023.12.001_bib56","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S1474-4422(20)30070-3","article-title":"Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open-label, multicentre, randomised, phase 2 trial","volume":"19","author":"Zhang","year":"2020","journal-title":"Lancet Neurol"},{"issue":"7","key":"10.1016\/j.mric.2023.12.001_bib57","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1056\/NEJMoa1900866","article-title":"Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder","volume":"381","author":"Pittock","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.mric.2023.12.001_bib58","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1002\/ana.26626","article-title":"Ravulizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder","volume":"93","author":"Pittock","year":"2023","journal-title":"Ann Neurol"},{"issue":"14","key":"10.1016\/j.mric.2023.12.001_bib59","first-page":"21","article-title":"Differential Effects of MS Therapeutics on B Cells-Implications for Their Use and Failure in AQP4-Positive NMOSD Patients","author":"Traub","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.mric.2023.12.001_bib60","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1046\/j.1471-4159.1999.0720001.x","article-title":"The structure and function of myelin oligodendrocyte glycoprotein","volume":"72","author":"Johns","year":"1999","journal-title":"J\u00a0Neurochem"},{"issue":"2","key":"10.1016\/j.mric.2023.12.001_bib61","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1006\/geno.1995.1137","article-title":"The human myelin oligodendrocyte glycoprotein (MOG) gene: complete nucleotide sequence and structural characterization","volume":"28","author":"Roth","year":"1995","journal-title":"Genomics"},{"issue":"2","key":"10.1016\/j.mric.2023.12.001_bib62","doi-asserted-by":"crossref","first-page":"281","DOI":"10.3390\/v14020281","article-title":"Viral Proteins with PxxP and PY Motifs May Play a Role in Multiple Sclerosis","volume":"14","author":"Pi","year":"2022","journal-title":"Viruses"},{"key":"10.1016\/j.mric.2023.12.001_bib63","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2023.1137998","article-title":"Pathophysiology of myelin oligodendrocyte glycoprotein antibody disease","volume":"14","author":"Corbali","year":"2023","journal-title":"Front Neurol"},{"key":"10.1016\/j.mric.2023.12.001_bib64","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2022.885218","article-title":"Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD): A Review of Clinical and MRI Features, Diagnosis, and Management","volume":"13","author":"Sechi","year":"2022","journal-title":"Front Neurol"},{"issue":"3","key":"10.1016\/j.mric.2023.12.001_bib65","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/S1474-4422(22)00431-8","article-title":"Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria","volume":"22","author":"Banwell","year":"2023","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.mric.2023.12.001_bib66","doi-asserted-by":"crossref","first-page":"960","DOI":"10.3389\/fneur.2020.00960","article-title":"The expanding clinical spectrum of myelin oligodendrocyte glycoprotein (MOG) antibody associated disease in children and adults","volume":"11","author":"Parrotta","year":"2020","journal-title":"Front Neurol"},{"issue":"10","key":"10.1016\/j.mric.2023.12.001_bib67","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.12732","article-title":"Comparison of Clinical Outcomes of Transverse Myelitis Among Adults With Myelin Oligodendrocyte Glycoprotein Antibody vs Aquaporin-4 Antibody Disease","volume":"2","author":"Mariano","year":"2019","journal-title":"JAMA Netw Open"},{"issue":"6","key":"10.1016\/j.mric.2023.12.001_bib68","doi-asserted-by":"crossref","first-page":"e503","DOI":"10.1212\/NXI.0000000000000503","article-title":"MOG antibodies in combined central and peripheral demyelination syndromes","volume":"5","author":"Vazquez Do Campo","year":"2018","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.mric.2023.12.001_bib69","article-title":"Brainstem and cerebellar involvement in MOG-IgG-associated disorder versus aquaporin-4-IgG and MS","author":"Banks","year":"2020","journal-title":"J\u00a0Neurol Neurosurg Psychiatr"},{"issue":"11","key":"10.1016\/j.mric.2023.12.001_bib70","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1001\/jamaneurol.2018.1814","article-title":"Association of MOG-IgG Serostatus With Relapse After Acute Disseminated Encephalomyelitis and Proposed Diagnostic Criteria for MOG-IgG-Associated Disorders","volume":"75","author":"L\u00f3pez-Chiriboga","year":"2018","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.mric.2023.12.001_bib71","series-title":"Anti-myelin oligodendrocyte glycoprotein (anti-MOG) meningoencephalitis","author":"Elfasi","year":"2023"},{"issue":"12","key":"10.1016\/j.mric.2023.12.001_bib72","doi-asserted-by":"crossref","first-page":"3180","DOI":"10.1111\/epi.17424","article-title":"Acute symptomatic seizures secondary to myelin oligodendrocyte glycoprotein antibody-associated disease","volume":"63","author":"Montalvo","year":"2022","journal-title":"Epilepsia"},{"issue":"6","key":"10.1016\/j.mric.2023.12.001_bib73","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1001\/jamaneurol.2021.0912","article-title":"Positive predictive value of myelin oligodendrocyte glycoprotein autoantibody testing","volume":"78","author":"Sechi","year":"2021","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.mric.2023.12.001_bib74","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.103746","article-title":"Implications of Low-Titer MOG Antibodies","volume":"59","author":"Levy","year":"2022","journal-title":"Mult Scler Relat Disord"},{"issue":"2","key":"10.1016\/j.mric.2023.12.001_bib75","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1136\/jnnp-2017-316880","article-title":"Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination","volume":"89","author":"Ramanathan","year":"2018","journal-title":"J\u00a0Neurol Neurosurg Psychiatr"},{"key":"10.1016\/j.mric.2023.12.001_bib76","article-title":"Treatment Response to Different Immunotherapies in Relapsing Myelin-Oligodendrocyte Glycoprotein Antibody - Associated Disease (MOGAD)","volume":"2023","author":"Elfasi","year":"2023","journal-title":"ACTRIMS Forum"},{"issue":"1","key":"10.1016\/j.mric.2023.12.001_bib77","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.42780","article-title":"Factors Associated With Relapse and Treatment of Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease in the United Kingdom","volume":"5","author":"Satukijchai","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"12","key":"10.1016\/j.mric.2023.12.001_bib78","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1093\/brain\/awx276","article-title":"Clinical presentation and prognosis in MOG-antibody disease: a UK study","volume":"140","author":"Jurynczyk","year":"2017","journal-title":"Brain"},{"issue":"2","key":"10.1016\/j.mric.2023.12.001_bib79","doi-asserted-by":"crossref","first-page":"e111","DOI":"10.1212\/WNL.0000000000009758","article-title":"Steroid-sparing maintenance immunotherapy for MOG-IgG associated disorder","volume":"95","author":"Chen","year":"2020","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.mric.2023.12.001_bib80","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1152\/physrev.00011.2013","article-title":"Physiological roles of aquaporin-4 in brain","volume":"93","author":"Nagelhus","year":"2013","journal-title":"Physiol Rev"}],"container-title":["Magnetic Resonance Imaging Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1064968923001150?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1064968923001150?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,3,29]],"date-time":"2024-03-29T07:06:54Z","timestamp":1711696014000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1064968923001150"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":80,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S1064968923001150"],"URL":"https:\/\/doi.org\/10.1016\/j.mric.2023.12.001","relation":{},"ISSN":["1064-9689"],"issn-type":[{"value":"1064-9689","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neuromyelitis Optica Spectrum Disorders and Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease","name":"articletitle","label":"Article Title"},{"value":"Magnetic Resonance Imaging Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mric.2023.12.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}